Detalhe da pesquisa
1.
New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
Brief Bioinform
; 25(2)2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343328
2.
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204).
Cancer
; 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412283
3.
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.
Cancer Cell Int
; 24(1): 120, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555429
4.
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Lancet Oncol
; 24(10): 1134-1146, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797632
5.
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.
Chin J Cancer Res
; 35(5): 526-535, 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37969958
6.
Identification of glycolysis-associated long non-coding RNA regulatory subtypes and construction of prognostic signatures by transcriptomics for bladder cancer.
Funct Integr Genomics
; 22(4): 597-609, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35420332
7.
Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms.
Oncologist
; 27(8): e625-e632, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35647908
8.
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
Oncologist
; 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445725
9.
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Cancer Immunol Immunother
; 71(8): 1897-1908, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984540
10.
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Cancer Immunol Immunother
; 71(10): 2371-2379, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35165764
11.
Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications.
Mol Cell Biochem
; 477(1): 213-223, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655417
12.
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Oncologist
; 26(10): e1693-e1703, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105207
13.
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Cancer Immunol Immunother
; 70(3): 857-868, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070260
14.
Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
BMC Cancer
; 21(1): 56, 2021 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33435909
15.
A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics.
Gastric Cancer
; 24(6): 1227-1241, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34095982
16.
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Future Oncol
; 17(11): 1339-1350, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33325251
17.
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(11): 1489-1499, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966810
18.
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(11): 1500-1512, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966811
19.
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
BMC Cancer
; 20(1): 760, 2020 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795349
20.
90-gene signature assay for tissue origin diagnosis of brain metastases.
J Transl Med
; 17(1): 331, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31570099